METHODOLOGY

BCC presents an analysis of each of the three key market segments that will be commercially important during the next 5 years: research tools, cancer diagnostics, and cancer therapeutics.

Based on our analysis, we analyze the potential applications of epigenomics in each of the major market segments, and forecast sales revenues for 2007 through 2012.

For research tools, the study presents a forecast from 2007 through 2012 for each of the important products and technologies. For cancer diagnostics, the report forecasts from 2007 through 2012 the demand for epigenetic-based test kits by cancer and disease type. Finally, this study forecasts from 2007 through 2012 the market for epigenetic drugs by cancer type.

INFORMATION SOURCES

We surveyed life science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, epigenetic biotechnology companies, and leading epigenomic research institutions. We also spoke with users of in vitro personalized medicine devices. In addition, we compiled data from secondary sources including industry, trade, and government.

ANALYST CREDENTIALS

Neil Izatt has more than 20 years experience at both high-technolory Fortune 500 companies and start-up technology firms. His experience includes strategy development, commercialization of high-technology products, and international expansion in various industries, including biotechnology, bioseparations, analytical separation, advanced materials, and metals separations. He holds a Master of Science Degree in Biotechnology and a Bachelor of Science Degree in Chemistry.

目录及图表

    Epigenomics: Emerging Opportunities in Biomarkets, Diagnostics and Therapeutics   $ 4850.00 
     Chapter 1 - SUMMARY   $ 150.00 
    Summary Table: GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS) 0  
    Summary Figure: GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, 2005-2012 ($ MILLIONS) 0  
     Chapter 2 - OVERVIEW   $ 381.00 
   INTRODUCTION 1  
    THE NEW PARADIGM OF EPIGENOMICS 1  
   Figure 1 EPIGENOMICS: A NEW PARADIGM 2  
   HOW EPIGENOMICS FITS WITHIN THE GENOMICS FIELD 3  
    Table 1 GENOMICS PLATFORMS 3  
   ELEMENTS OF THE EPIGENOME COVERED IN THIS REPORT 4  
   Table 2 ELEMENTS OF THE EPIGENOME COVERED IN THIS REPORT 5  
   MARKET POTENTIAL OF EPIGENOMICS 6  
    Table 3 GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS) 6  
   KEY EPIGENOMICS PRODUCTS 7  
    RESEARCH TOOLS AND REAGENTS 7  
    DIAGNOSTICS 7  
   DRUGS 8  
    DRIVING FORCES FOR GROWTH IN EPIGENOMICS 8  
   IMPORTANCE OF EPIGENETIC TECHNOLOGY 9  
   Figure 2 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT 10  
   LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES 11  
   HISTORICAL BACKGROUND 12  
    Table 4 HISTORICAL OVERVIEW OF EPIGENETICS 12  
   THE EPIGENOMICS INDUSTRY 13  
    Table 5 EPIGENOMICS INDUSTRY 13  
   THE EPIGENOMICS INDUSTRY (CONTINUED) 14  
     Chapter 3 - EPIGENETIC TECHNOLOGY   $ 409.00 
   INTRODUCTION 15  
    TWO MAIN EPIGENOMIC ANALYSIS TECHNOLOGIES 15  
   Table 6 TWO TYPES OF EPIGENOMIC ANALYSIS TECHNOLOGIES 16  
    STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES 16  
    Table 7 STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES 16  
   DNA AND HISTONE ANALYSIS WORKFLOW 17  
   Figure 3 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS 18  
    DNA METHYLATION 18  
    METHYLATED CYTOSINE-A FIFTH BASE 18  
   Figure 4 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 19  
    BIOLOGICAL ROLE OF DNA METHYLATION 19  
   Table 8 BIOLOGICAL ROLES OF DNA METHYLATION 20  
   Table 8 (CONTINUED) 21  
    DNA METHYLTRANSFERASE ENZYMES 21  
   CPG ISLANDS 22  
   Table 9 CPG ISLANDS: SUBJECT TO DNA METHYLATION 23  
   HISTONE METHYLATION AND ACETYLATION 24  
    HISTONES 24  
   Figure 5 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC 25  
   HISTONE ACETYLATION AND METHYLATION ENZYMES 26  
    Figure 6 HISTONE ACETYLATION AND METHYLATION ENZYMES 26  
   Histone Acetyl Transferases (HAT Enzymes) 27  
    Histone Deacetylases (HDAC Enzymes) 27  
    Table 10 HDAC ENZYMES CLASSES 27  
   Histone Methyltransferases and Demethylases 28  
    INAPPROPRIATE METHYLATION AND ACETYLATION 28  
   Table 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION 29  
     Chapter 4 - EPIGENOMIC ANALYSIS TECHNOLOGIES   $ 681.00 
   ROLE OF EPIGENOMIC RESEARCH TOOLS 30  
   DNA METHYLATION RESEARCH TOOLS 31  
    Table 12 DNA METHYLATION ANALYSIS ASSAYS 31  
   DNA METHYLATION ANALYSIS WORKFLOW 32  
   Figure 7 METHYLATED DNA ANALYSIS WORKFLOW 33  
    ANALYSIS TYPES BY WORKFLOW 33  
    Table 13 EXAMPLES OF DNA METHYLATION ASSAYS 33  
   DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES 34  
    Table 14 COMPARISON OF UPSTREAM EPIGENOMIC RECOGNITION TECHNOLOGIES 34  
   RESTRICTION ENZYME-BASED METHODS 35  
   Figure 8 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES 36  
    BISULFITE-BASED METHODS 36  
   Bisulfite-Based Methods (Continued) 37  
   Figure 9 BISULFITE CONVERSION OF DNA 38  
   Analysis of Low Complexity DNA-A Unique Challenge for Bisulfite Methods 39  
   ANTIBODY-BASED METHODS 40  
   CHALLENGE OF HIGH BACKGROUND METHYLATED DNA 41  
   DNA METHYLATION ANALYSIS: DOWNSTREAM TECHNOLOGIES 42  
    GENOME WIDE DNA METHYLATION ANALYSIS 42  
    Table 15DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION 42  
   GENOME WIDE DNA … (CONTINUED) 43  
   HIGH THROUGHPUT PLATFORMS 44  
    HISTONE EPIGENOMIC ANALYSIS TECHNOLOGIES 44  
    CHROMATIN IMMUNOPRECIPITATION 44  
   CHIP-ON-CHIP 45  
   Figure 10 CHIP-ON-CHIP PROCEDURE 46  
   Table 16 CHIP ASSAYS 47  
    Table 17 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 47  
   MICROARRAYS 48  
    FEATURE DENSITY 48  
    Figure 11 MICROARRAY FEATURE DENSITY 48  
   RESOLUTION 49  
    Figure 12 MICROARRAY RESOLUTION 49  
    GENOME CONTENT 49  
   Table 18 MICROARRAY GENOME CONTENT 50  
   Table 19 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS 51  
    SERIAL ANALYSIS OF GENE EXPRESSION 51  
   ANTIBODIES 52  
   ALTERNATIVES TO ANTIBODIES IN UPSTREAM STEP 53  
    DNA ADENINE METHYLTRANSFERASE IDENTIFICATION (DAM ID) 53  
   DNA Adenine Methyltransferase … (Continued) 54  
     Chapter 5 - DNA METHYLATION BIOMARKERS   $ 763.00 
   FROM ANALYSIS TO BIOMARKERS 55  
   OPPORTUNITIES FOR BIOTECHNOLOGY COMPANIES IN DIAGNOSTICS 56  
   WHAT IS A BIOMARKER? 57  
    DNA METHYLATION AS A CANCER BIOMARKER 57  
    DNA METHYLATION IN CANCER ETIOLOGY 57  
   Table 20 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS 58  
   Table 21 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION 59  
    Cell Cycle Control 59  
    Cell Invasion and Adhesion 59  
    DNA Damage Repair 59  
   Growth Factor Response 60  
    Regulation of Apoptosis 60  
    Hormonal Response 60  
    Cytokine Signaling 60  
   Table 22 CANCER-RELATED EPIGENETIC CHANGES 61  
   MOLECULAR BIOMARKER TECHNOLOGY COMPARISON 62  
    Table 23 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS 62  
    Occurrence within the Genome 62  
   Inheritance in Progenitor Cells 63  
    DNA Base Mutation 63  
    Binary Signal 63  
    Presence of Background Signal 63  
   Stable Change in Biomarker Status 64  
    Stability of Sample Material 64  
    Detection of First Hit 64  
   Occurrence in Early or Pre-Cancers 65  
    Tissue Sample Range 65  
    Test Complexity 65  
   ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION 66  
   EPIGENETIC BIOMARKER CANCER GENES 67  
   Table 24 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS 68  
    EPIGENETIC BIOMARKERS FOR NON-CANCER DISEASES 68  
   Table 25 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS 69  
    BIOMARKER DISCOVERY PROCESS 69  
   METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES 70  
    Table 26 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY 70  
   Table 26 (CONTINUED) 71  
    GENOME-WIDE SCANNING TO HUNT FOR BIOMARKERS 71  
   LARGE SCALE REGIONAL EPIGENOMICS PROJECTS 72  
   Table 27 REGIONAL EPIGENOMICS INITIATIVES 73  
   Table 27 (CONTINUED) 74  
    EUROPE 74  
   UNITED STATES 75  
    ASIA 75  
   HUMAN EPIGENOME PROJECT WILL AID IN THE DISCOVERY OF NEW METHYLATION MARKERS 76  
    Table 28 METHYL VARIABLE POSITIONS - MVPS 76  
   Table 29 HUMAN EPIGENOME PROJECT: METHYL VARIABLE POSITION ANALYSIS OBJECTIVES 77  
    CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS 77  
   CASE STUDY (CONTINUED) 78  
   DEVELOPMENT STAGES FOR AN IN VITRO DIAGNOSTIC 79  
    PHASE 1: BIOMARKER DISCOVERY 79  
    PHASE 2: BIOMARKER VALIDATION 79  
   PHASE 3: FORMAL KIT DEVELOPMENT 80  
    PHASE 4: CLINICAL VALIDATION 80  
   TYPES OF CANCER METHYLATION MARKERS 81  
    FUTURE STATUS OF DNA METHYLATION BIOMARKERS 81  
   Table 30 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS 82  
     Chapter 6 - EPIGENETIC CANCER THERAPIES   $ 763.00 
   INTRODUCTION 83  
    EPIGENETICS IN TUMORIGENESIS 83  
   EPIGENETIC DRUG TARGETS 84  
    Table 31 EPIGENETIC GENES ALTERED IN HUMAN CANCERS 84  
   Table 31 (CONTINUED) 85  
   HISTONE METHYLATION AND ACETYLATION ENZYME DRUG TARGETS 86  
   Figure 13 HISTONE DEACETYLASE REACTION 87  
   Table 32 STATUS OF EPIGENETIC ENZYMES THAT TARGET HISTONES 88  
    HISTONE DEACETYLACE INHIBITORS 88  
   HDAC ENZYMES AS DRUG TARGETS 89  
   HDAC INHIBITOR DRUG CLASSES 90  
   Table 33 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY 91  
    HYDROXAMATES 91  
   Figure 14 TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR 92  
    ALIPHATIC ACIDS 92  
   Figure 15 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR 93  
    CYCLIC TETRAPEPTIDES 93  
    Figure 16 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR 93  
   BENZAMIDES 94  
    Table 34 MS-275, A BENZAMIDE CLASS HDAC INHIBITOR 94  
    KEY HDAC INHIBITOR TECHNOLOGY TRENDS 94  
   Table 35 KEY HDAC INHIBITOR DRUG TRENDS 95  
    ENZYME SELECTIVITY 95  
   Enzyme Selectivity (Continued) 96  
   Table 36 HDAC INHIBITOR CLASS I AND II SELECTIVITY (IC50 RATIO) 97  
    POTENCY 97  
    IMPROVEMENTS IN DRUG-LIKE PROPERTIES 97  
   SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE 98  
    Figure 17 DISEASE HDAC ISOFORM PROFILE 98  
   CHEMICAL DESIGN IS THE KEY TO SELECTIVITY 99  
    Figure 18 STRUCTURAL COMPONENTS MOTIFS OF HDAC INHIBITORS 99  
   HDAC INHIBITORS IN COMBINATION THERAPIES 100  
   HDAC INHIBITORS IN … (CONTINUED) 101  
   Table 37 HDAC INHIBITOR DRUG COMPANIONS 102  
   HDAC INHIBITORS IN … (CONTINUED) 103  
   HDAC INHIBITORS AS THERAPIES FOR NON-CANCER DISEASES 104  
    CARDIAC DISEASE 104  
   DERMATOLOGICAL DISORDERS 105  
   PARASITIC DISEASES 106  
    NEURODEGENERATIVE DISEASES 106  
    DIABETES 106  
   INFLAMMATORY DISEASES 107  
    DNA METHYLTRANSFERASE INHIBITORS (DNMT) 107  
    Figure 19 LEAD DNMT INHIBITOR COMPOUNDS 107  
   NUCLEOSIDE ANALOGUES 108  
    Figure 20 DNMT INHIBITORS AND MODE OF ACTION 108  
   NON-NUCLEOSIDE ANALOGUES 109  
    ANTISENSE OLIGONUCLEOTIDES 109  
    FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 109  
   Table 38 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 110  
     Chapter 7 - EPIGENETICS ASSISTED REPRODUCTIVE TECHNOLOGIES   $ 136.00 
   SOMATIC CELL NUCLEAR TRANSFER 111  
    Figure 21 SOMATIC CELL NUCLEAR TRANSFER 111  
   Table 39 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER 112  
    Table 40 EPIGENETIC ALTERATIONS IN ASSISTED REPRODUCTIVE DISORDERS 112  
   APPLICATIONS OF EPIGENOMICS IN CLONING 113  
    REPROGRAMMING FACTORS 113  
    Figure 22 EPIGENETIC PROGRAMMING OF STEM CELLS 113  
   CELLULAR IDENTIFICATION AND QUALITY CONTROL ASSAYS 114  
   Cellular Identification … (Continued) 115  
     Chapter 8 - MARKET GROWTH DRIVING FORCES   $ 136.00 
   INTRODUCTION 116  
    Table 41 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS 116  
    KEY GROWTH DRIVERS 116  
   Table 42 PRIMARY FORCES DRIVING EPIGENOMICS PRODUCTS GROWTH 117  
    DEVELOPMENT OF NOVEL EPIGENOMICS RESEARCH TOOLS 117  
    CREATION OF EPIGENETIC MAPS 117  
   SCOPE OF EPIGENETIC ANALYSIS 118  
    NEED FOR EARLY CANCER DETECTION 118  
   NEED FOR BETTER CANCER THERAPIES 119  
    GROWTH IN LIFE SCIENCE RESEARCH BUDGETS 119  
    PERSONALIZED MEDICINE TRENDS 119  
   RESEARCH IN EPIGENETIC PROCESSES 120  
     Chapter 9 - EPIGENOMIC RESEARCH TOOLS MARKETS   $ 545.00 
   PRODUCTS WITHIN RESEARCH TOOLS 121  
    EPIGENOMIC KITS 121  
    REAGENTS 121  
    MICROARRAYS 121  
    GLOBAL SALES BY TECHNOLOGY 121  
   Table 43 GLOBAL MARKET FORECAST FOR EPIGENOMICS RESEARCH TOOL KITS BY TYPE THROUGH 2012 ($ MILLION) 122  
   GLOBAL SALES BY PRODUCT 123  
    Table 44 GLOBAL MARKET FORECAST FOR EPIGENOMIC ANALYSIS RESEARCH TOOLS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 123  
   EPIGENOMIC KIT SALES BY TECHNOLOGY 124  
   Table 45 GLOBAL MARKET FORECAST FOR EPIGENETIC ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 125  
    DNA METHYLATION ANALYSIS KIT MARKET 125  
   DNA METHYLATION … (CONTINUED) 126  
   Table 46 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOL KITS BY ANALYSIS OBJECTIVE THROUGH 2012 ($ MILLIONS) 127  
   Table 47 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 128  
   Table 48 GLOBAL MARKET FORECAST FOR DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 129  
   Table 49 GLOBAL MARKET FORECAST FOR DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 130  
    HISTONE ANALYSIS KIT MARKET 130  
   Table 50 GLOBAL MARKET FORECAST FOR VALUE OF HISTONE ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 131  
    MICROARRAY MARKET 131  
    MICROARRAYS AS DOWNSTREAM ANALYSIS TOOL 131  
   Microarray Differentiation 132  
    Figure 23 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS 132  
    Table 51 MICROARRAY PROBES 132  
   Microarray … (Continued) 133  
   MICROARRAY ANALYSIS PLATFORMS IN THE CLINIC 134  
    Table 52 CLINICAL STATUS OF MICROARRAY PLATFORMS 134  
   Microarray Analysis … (Continued) 135  
   FUTURE MARKET POSITION OF MICROARRAYS 136  
    EPIGENOMIC MICROARRAY MARKET 136  
   Table 53 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS) 137  
    Table 54 GLOBAL VALUE OF EPIGENOMIC RESEARCH TOOLS MICROARRAYS BY ANALYSIS THROUGH 2012 ($ MILLIONS) 137  
   Table 55 GLOBAL VALUE OF DIAGNOSTIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS) 138  
   REAGENTS MARKET 139  
    Table 56 GLOBAL VALUE OF EPIGENOMIC REAGENTS BY MARKET THROUGH 2012 ($ MILLIONS) 139  
    Table 57 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 139  
   REAGENTS MARKET (CONTINUED) 140  
     Chapter 10 - EPIGENETIC BIOMARKER AND DIAGNOSTICS MARKETS   $ 1035.00 
   OVERVIEW OF CANCER DIAGNOSTICS MARKET 141  
    Table 58 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS MARKETS BY SEGMENT THROUGH 2012 ($ MILLIONS) 141  
   CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS 142  
   Table 59 TARGETED THERAPY CANCER DRUG COMPOUNDS IN DEVELOPMENT 143  
    METHYLATION BIOMARKERS CLINICAL DEVELOPMENT STATUS 143  
   Table 60 DEVELOPMENT STATUS OF SELECTED METHYLATION BIOMARKERS BY CANCER TYPE 144  
    CANCER DIAGNOSTIC MARKET SEGMENTS 144  
   ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS 145  
   Figure 24 CANCER SCREENING OPPORTUNITY MATRIX FOR EPIGENETIC TESTS IN DEVELOPMENT 146  
   Figure 25 NEW EPIGENETIC SCREENING PARADIGM 147  
   SENSITIVITY AND SPECIFICITY 148  
    Figure 26 SENSITIVITY AND SPECIFICITY 148  
   STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS 149  
    COLORECTAL CANCER 149  
    Colorectal Cancer Screening Tests 149  
   Table 61 CURRENT SCREENING AND DIAGNOSTIC TESTS FOR COLORECTAL CANCER 150  
   DNA-based Colorectal Screening Tests 151  
    Epigenetics-based Colorectal Screening Tests 151  
   Table 62 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS 152  
   Colorectal Cancer Non-screening Tests 153  
    BLADDER CANCER 153  
    BREAST CANCER 153  
   Screening for Breast Cancer 154  
    Relapse Risk Prediction 154  
   Therapy Prediction 155  
   PROSTATE CANCER 156  
   LUNG CANCER 157  
   OVARIAN CANCER 158  
    Table 63 OVARIAN CANCER POTENTIAL SCREENING TESTS 158  
   CERVICAL CANCER 159  
    PANCREATIC CANCER 159  
   GASTRIC CANCER 160  
    PEDIATRIC CANCERS 160  
   PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS 161  
    KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST 161  
   Table 64 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC KIT 162  
   AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTIC TESTS 163  
   Table 65 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTIC TEST KITS BY MARKET SEGMENT ($ MILLIONS) 164  
   AVAILABLE MARKET FOR … (CONTINUED) 165  
   Table 66 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTICS TEST KITS BY INDICATION ($ MILLIONS) 166  
    Table 67 CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2006 166  
   Table 67 (CONTINUED) 167  
    Table 68 BREAST CANCER DIAGNOSTICS PRODUCT SEGMENTS 167  
   AGING POPULATIONS CONTRIBUTE TO DIAGNOSTICS MARKET POTENTIAL 168  
    Table 69 PROJECTED INCREASE IN AGE 65+ POPULATION BY REGION 168  
   DNA METHYLATION DIAGNOSTICS PIPELINE 169  
    Table 70 PIPELINE FOR DNA METHYLATION DIAGNOSTICS TESTS 169  
   Table 70 (CONTINUED) 170  
    SCREENING TESTS 170  
    Prostate Cancer Screening Tests 170  
   Colorectal Cancer Screening Tests 171  
    Breast Cancer Screening Tests 171  
    Lung Cancer Screening Tests 171  
    Bladder Cancer Screening Tests 171  
   MONITORING, CLASSIFICATION, AND PHARMACODIAGNOSTIC TESTS 172  
    Breast Cancer Classification Tests 172  
    Prostate Cancer Diagnostics Tests 172  
   Bladder Cancer Monitoring Tests. 173  
    Other Non-Screening Tests 173  
    EPIGENETICS BASED DIAGNOSTICS KITS MARKET SIZE 173  
   Table 71 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY MARKET THROUGH 2012 ($ MILLIONS) 174  
    Table 72 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION THROUGH 2012 ($ MILLIONS) 174  
   Table 73 2012 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION AND SEGMENT ($ MILLIONS) 175  
   EPIGENETIC DIAGNOSTICS KITS MARKET BY TECHNOLOGY 176  
   Table 74 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 177  
   EPIGENETIC DIAGNOSTICS … (CONTINUED) 178  
     Chapter 11 - MARKETS FOR EPIGENETIC DRUGS   $ 872.00 
   OVERVIEW 179  
    THE CANCER DRUG MARKET 179  
   Table 75 GLOBAL MARKET FORECAST FOR SELECTED CANCER DRUGS BY, THROUGH 2012 ($ MILLIONS) 180  
    TARGETED THERAPEUTICS 180  
   CANCER DRUG MARKET GROWTH DRIVING FORCES 181  
   CANCER DRUG … (CONTINUED) 182  
   EPIGENETIC-BASED DRUGS AS CANCER THERAPIES 183  
   PROOF OF PRINCIPLE OF EPIGENETIC DRUGS ESTABLISHED 184  
    EPIGENETIC THERAPIES BEYOND CANCER 184  
   EPIGENETIC DRUG MARKET FORECAST 185  
    Table 76 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS) 185  
   Table 77 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY CLASS, THROUGH 2012 ($ MILLIONS) 186  
    INITIAL FOCUS ON HEMATOLOGICAL CANCERS 186  
   Table 78 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES 187  
    MARKET SIZE FOR HEMATOLOGICAL CANCER DRUGS 187  
   Table 79 GLOBAL MARKET FORECAST OF HEMATOLOGICAL CANCER DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS) 188  
   Table 80 COMPARISON OF THREE NEW MDS DRUGS 189  
   MARKET SIZE … (CONTINUED) 190  
   HDAC INHIBITORS MARKETS 191  
    STRATEGIC OPPORTUNITIES IN HDAC INHIBITORS 191  
    Table 81 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT 191  
   HDAC INHIBITORS IN DEVELOPMENT AND CLINICAL TRIALS 192  
   Table 82 HDAC INHIBITOR DRUG CANDIDATES IN CLINICAL TRIALS 193  
   Zolinza 194  
    PXD-101 194  
   Table 83 PXD-101 CLINICAL TRIALS STATUS 195  
   NVP-LAQ824 196  
    Bacacea, Avugane, Savacol 196  
    Romidepsin 196  
   Table 84 ROMIDEPSIN CLINICAL TRIALS STATUS 197  
   MS-275 198  
    CI 994 198  
    MGCD0103 198  
   Table 85 MBCD0103 INHIBITS SELECTED HDAC ENZYMES 199  
    PCI-24781 199  
    SRT-501 199  
   HDAC INHIBITOR DRUG MARKET SIZE BY INDICATION 200  
    Table 86 GLOBAL MARKET FORECAST FOR HDAC INHIBITOR DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS) 200  
   HDAC INHIBITOR MARKET SIZE BY TECHNOLOGY 201  
   Table 87 GLOBAL VALUE OF HDAC INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 202  
    DNMT INHIBITORS MARKET 202  
    DNMT INHIBITORS IN CLINICAL TRIALS 202  
    Table 88 DNMT INHIBITORS IN CLINICAL TRIALS AND UNDER DEVELOPMENT 202  
   Table 88 (CONTINUED) 203  
    Nucleoside Analogues 203  
    5-azacytidine (Vidaza) 203  
   5-aza-2'-deoxycitidine (Decitabine, Dacogen) 204  
   Zebularine 205  
    DHAC (Dihydro-5-azacytidine) 205  
   Non-Nucleoside Analogues 206  
    MG98 206  
    Hydralazine 206  
   Preclinical Non-Nucleosides 207  
    FDA-APPROVED DNMT INHIBITORS 207  
    Table 89 FDA APPROVED DNMT INHIBITOR DRUGS 207  
   MARKET SIZE FOR DNMT INHIBITORS 208  
    Table 90 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS) 208  
   Table 91 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS) 209  
    ALTERNATIVE DEMETHYLATION THERAPEUTIC APPROACHES 209  
   CLONING AND TISSUE ENGINEERING MARKETS 210  
    Table 92 GLOBAL VALUE OF CLONING AND TISSUE ENGINEERING EPIGENETIC KITS THROUGH 2012 ($ MILLIONS) 210  
     Chapter 12 - COMPETITIVE DYNAMICS   $ 163.00 
   RESEARCH TOOLS 211  
   Table 93 EPIGENOMIC RESEARCH TOOLS SUPPLIERS 212  
   DIAGNOSTICS 213  
    Table 94 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS 213  
   Table 94 (CONTINUED) 214  
    Table 95 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES 214  
   EPIGENETIC DRUGS 215  
   Table 96 COMPETITIVE LANDSCAPE FOR EPIGENETIC DRUG COMPANIES 216  
     Chapter 13 - PATENTS   $ 136.00 
   RESEARCH TOOLS 217  
    Table 97 PATENTS AND PATENT APPLICATION STATUS OF EPIGENOMICS AG RESEARCH TOOLS 217  
   BIOMARKERS AND DIAGNOSTICS 218  
   Table 98 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 219  
   PHARMACEUTICALS 220  
    Table 99 HDAC INHIBITOR PATENT CLAIMS: 2004-2006 220  
   Table 99 (CONTINUED) 221  
     Chapter 14 - COMPANY PROFILES   $ 1253.00 
   ABBOTT LABORATORIES 222  
   ABCAM PLC. 223  
    ACTIVE MOTIF 223  
   AFFYMETRIX 224  
   AGILENT TECHNOLOGIES, INC. 225  
    APPLIED BIOSYSTEMS 225  
   AVIVA SYSTEMS BIOLOGY 226  
   BAYER AG 227  
    BIOSERVE BIOTECHNOLOGIES, LTD. 227  
   BIOVISION 228  
    CELLARTIS AB 228  
   CELLCENTRIC LTD. 229  
    CHIPSCREEN BIOSCIENCES LTD. 229  
   CHROMA THERAPEUTICS 230  
   CURAGEN 231  
    Table 100 CURAGEN STRATEGIC ALLIANCES 231  
   EPIGENOMICS AG 232  
   EPIGENOMICS AG (CONTINUED) 233  
   EPIGENTEK 234  
   EPIONTIS GMBH 235  
   ELIXIR PHARMACEUTICALS, INC. 236  
   ENTREMED, INC. 237  
    ENVIVO PHARMACEUTICALS 237  
   ES CELL INTERNATIONAL PTE LTD 238  
    EXONHIT THERAPEUTICS SA 238  
   F. HOFFMANN-LA ROCHE, LTD. 239  
   GENPATHWAY, INC. 240  
   GILEAD SCIENCES (MYOGEN) 241  
    GLOUCESTER PHARMACEUTICALS 241  
   HUYA BIOSCIENCE INTERNATIONAL 242  
   ILLUMINA, INC. 243  
    KALYPSYS, INC. 243  
   KARUS THERAPEUTIC LTD 244  
   LEO PHARMA 245  
    MERCK & CO. INC. 245  
   METHYLGENE 246  
   Table 101 METHYLGENE EPIGENETIC PRODUCT PIPELINE 247  
   MGI PHARMA, INC. 248  
   MGI PHARMA, INC. (CONTINUED) 249  
   MILLIPORE (CHEMICON/UPSTATE) 250  
   NIMBLEGEN SYSTEMS, INC. 251  
    NOVARTIS 251  
   ONCOMETHYLOME SCIENCES S.A. 252  
    Biomarker Identification and Development Partners 252  
    Kit Development, Regulatory Review, and Mass Market of Kits 252  
   ORION GENOMICS 253  
   ORION GENOMICS (CONTINUED) 254  
   PANOMICS, INC. 255  
   PHARMACYCLICS 256  
    PHARMION CORPORATION 256  
   Table 102 PHARMION EPIGENETIC DRUG COMBINATION THERAPIES IN CLINICAL TRIALS 257  
   Table 103 POTENTIAL PHARMION INTRA-PORTFOLIO DRUG COMBINATIONS 258  
    QUIAGEN GMBH 258  
   RUBICON GENOMICS 259  
   S*BIO PTE LTD1 260  
   SCHERING AG 261  
    SCHERING PLOUGH CORPORATION 261  
   SEQUENOM 262  
   SEQWRIGHT 263  
    SIRTRIS PHARMACEUTICALS 263  
   TAIHO PHARMACEUTICALS 264  
    TAKEDA PHARMACEUTICAL COMPANY LIMITED 264  
   TOPOTARGET A/S 265  
    Table 104 TOPOTARGET'S HDAC INHIBITOR PATENT PORTFOLIO 265  
   Table104 (CONTINUED) 266  
    VERIDEX LLC 266  
   ZYMO RESEARCH 267